Core Viewpoint - The article discusses the significant decline in the stock price of Aquestive Therapeutics, Inc. (AQST) following a downgrade by Cantor, which reduced its price target from $15 to $8 due to concerns over the FDA's review process for its product Anaphylm, leading to potential delays and substantial losses for investors [1][6]. Group 1: Stock Performance and Analyst Reactions - AQST shares fell from $6.21 to $3.91, a loss of $2.30 per share, after the FDA identified deficiencies in its Anaphylm NDA [2]. - Analysts had previously built their models on management's assurances of a timely FDA approval, which were later contradicted by the FDA's findings [2][3]. - The rapid reassessment by analysts following the January 9 disclosure highlights a critical disconnect between management's portrayal of the FDA review and the actual deficiencies flagged by the FDA [3][5]. Group 2: Implications for Investors - The downgrades by analysts reflect the market's reliance on management's statements regarding FDA progress, leading to significant investor losses when those statements proved inconsistent with the FDA's findings [4][5]. - Oppenheimer's report indicated that the situation could lead to a worst-case scenario where shares might drop below cash value, depending on the FDA's considerations [6]. - The lead plaintiff deadline for investors seeking to recover losses is set for May 4, 2026 [7].

Group 1: Healthcare Stocks Overview - Many healthcare stocks, including small-cap biotech companies, are trading below $50 per share, but many are high-risk investments that may not yield long-term wealth for investors [1] - There are high-quality healthcare corporations available for investment at this price point, excluding fractional shares [1] Group 2: Pfizer and Novo Nordisk - Pfizer's shares are currently priced just under $27, trading at 9x forward earnings, significantly lower than the healthcare industry's average forward price-to-earnings of 17.8 [2] - Pfizer has faced inconsistent financial results, primarily due to lower sales from its coronavirus franchise, but is expected to improve as dependence on these products declines [3] - Novo Nordisk's stock price is around $39 with a forward price-to-earnings ratio of 10.4, and it is well-positioned to benefit from the expanding weight-loss market [3] - Novo Nordisk's weight-loss medicines, such as Wegovy, are leaders in their niches, and the company has several pipeline candidates that could receive approval in the coming years [4] Group 3: Exelixis - Exelixis, while not a major name in biotech, has established a niche in oncology with its therapy Cabometyx, which treats certain forms of liver and kidney cancer [5] - The company has been reporting growing revenue and earnings, and it may achieve further label expansions for Cabometyx before facing generic competition in early 2030 [5]

Core Viewpoint - AIM ImmunoTech Inc. has received full approval for a Japanese patent covering the use of Ampligen in combination with checkpoint inhibitors for cancer treatment, particularly pancreatic cancer, which is expected to see a significant increase in burden by 2030 [1][2]. Group 1: Patent and Intellectual Property - The Japanese patent covers the use of Ampligen in combination with checkpoint inhibitors for treating various cancer types, including pancreatic cancer [2]. - AIM holds additional patents in the U.S. and the Netherlands for similar uses of Ampligen, with expiration dates in August 2039 and December 2039, respectively [2]. - The company plans to expand its intellectual property portfolio by pursuing orphan drug designation in Japan for Ampligen in treating pancreatic cancer, complementing existing designations in the U.S. and EU [3]. Group 2: Market Context and Strategy - Japan is identified as a key global market for health, with significant expected increases in pancreatic cancer cases by 2030 [1]. - The company emphasizes its commitment to developing Ampligen for late-stage pancreatic cancer, addressing a critical unmet health need [3]. - The patent's approval is part of AIM's broader development and commercialization strategy [3]. Group 3: Product Information - Ampligen (rintatolimod) is described as a dsRNA and highly selective TLR3 agonist immuno-modulator that has demonstrated broad-spectrum activity in clinical trials [4].

Core Viewpoint - The U.S. Food and Drug Administration has approved Johnson & Johnson's oral pill for psoriasis, providing a more convenient treatment option for patients [1] Company Summary - Johnson & Johnson has received FDA approval for a new oral medication aimed at treating psoriasis, which is expected to enhance patient convenience and adherence to treatment [1] Industry Summary - The approval of this oral pill signifies a potential shift in the psoriasis treatment landscape, as it offers an alternative to existing therapies, which may include injections or topical treatments [1]

Core Insights - Amarin Corporation supports the inclusion of hypertriglyceridemia treatment in broader dyslipidemia management as per the 2026 ACC/AHA guidelines, emphasizing the need for comprehensive cardiovascular risk management [1][3][9] Company Overview - Amarin is dedicated to advancing cardiovascular disease treatment and has a global branded product, VASCEPA, which is FDA-approved and has shown proven efficacy and safety [10] - VASCEPA has been prescribed over 30 million times globally and is the first oral therapy to reduce cardiovascular events by 25% when used alongside statin therapy in high-risk patients [5][15] Industry Context - The updated dyslipidemia guidelines reflect a shift towards lifelong prevention-first management, encouraging early screening and addressing residual cardiovascular risk beyond LDL-C levels [3][4] - Elevated triglyceride levels are recognized as a significant contributor to cardiovascular disease, necessitating complementary therapies beyond statin monotherapy [4][6] - The guidelines support the use of evidence-based therapies like icosapent ethyl (IPE) for patients at high cardiovascular risk despite optimized statin therapy [6][8] Clinical Evidence - The REDUCE-IT trial demonstrated that high-dose icosapent ethyl significantly reduces cardiovascular events in patients with elevated triglycerides, reinforcing its role in managing residual cardiovascular risk [11][12] - The 2026 guidelines highlight the limitations of certain triglyceride-lowering agents, such as fenofibrates, which do not reduce cardiovascular risk when combined with statin therapy [7][8] Economic Implications - The emphasis on reducing residual cardiovascular risk has important health economic implications, as cardiovascular events are a leading driver of healthcare costs [9]

Business and pipeline update March 18, 2026 © Copyright 2026 Ovid Therapeutics Forward-looking statements This presentation includes certain disclosures by Ovid that contain "forward-looking statements" including, without limitation statements regarding: the reproducibility and durability of any favorable results initially seen to date in clinical trials; the potential therapeutic opportunity of OV329, OV4071 and other compounds from Ovid's library of direct activators of KCC2; the expected timing of initia ...

Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on selling and marketing FDA-approved prescription pharmaceutical products for dermatological conditions [4] - The company currently markets eight branded FDA-approved prescription drugs aimed at treating common skin conditions [4] - Journey Medical was founded by Fortress Biotech, Inc. and is located in Scottsdale, Arizona [4] Financial Results Announcement - Journey Medical will release its year-end 2025 financial results after U.S. financial markets close on March 25, 2026 [1] - A conference call and audio webcast will be held on March 25, 2026, at 4:30 p.m. ET to discuss the financial results and provide a corporate update [1] Conference Call Details - Interested parties in the U.S. can dial 1-866-777-2509 for domestic calls or 1-412-317-5413 for international calls to join the conference call [2] - Participants are encouraged to dial in approximately 10 minutes prior to the scheduled start time [2] - A live audio webcast will be available on the Investors section of Journey Medical's website and will remain accessible for replay for about 30 days after the conference call [3]

Core Insights - Eli Lilly and Company (NYSE: LLY) is viewed as a strong ethical investment option according to Reddit discussions [1] - HSBC downgraded Eli Lilly from Hold to Reduce, lowering the price target from $1,070 to $850, citing elevated expectations for the obesity market [1] - RBC Capital initiated coverage on Eli Lilly, highlighting its long-term leadership potential in the obesity market despite challenges [2] Market Analysis - HSBC estimates the total addressable market for obesity treatments to be over $150 billion, projecting it to be between $80 billion and $120 billion by 2032, with significant price competition anticipated [1] - The firm also noted that Eli Lilly's planned price cuts for obesity medications in 2026 could pose challenges, although volume growth is expected to continue [2] Investment Plans - Eli Lilly plans to invest $3 billion in China over the next decade to enhance production capacity for its experimental type-2 diabetes and obesity treatment, orforglipron [3] - The company has submitted a marketing application for orforglipron to China's drug regulator, aiming for approval by the end of 2025 [3] Company Overview - Eli Lilly develops, manufactures, discovers, and sells pharmaceutical products across various therapeutic areas, including oncology, diabetes, immunology, and neuroscience [4]

UPDATE OF THE FINANCIAL CALENDAR FOR 2026 Hørsholm 18 March 2026 Company announcement no 2 Pharma Equity Group A/S updates its financial calendar for 2026. For technical reasons, the publication of the annual report is being postponed from 18 March 2026 to 25 March 2026. The date of the annual general meeting remains unchanged at 16 April 2026. Pharma Equity Group2026 Financial Calendar ​March 4Deadline for shareholder proposals - Annual General meeting​ ​March 25 ​Annual Report 2025​ April 16Annual Genera ...

Core Viewpoint - Red Light Holland Corp. has engaged Kala Bio's Researgency.ai platform to enhance the clinical development strategy for its psilocybin drug candidate PEX010, aiming to leverage AI for improved research capabilities and accelerated drug development timelines [1][3][7]. Group 1: Company Developments - Red Light has entered a definitive arrangement agreement to acquire Filament Health Corp., which includes a portfolio of 76 issued patents across 15 patent families, significantly enhancing its intellectual property in botanical psilocybin drug development [2]. - PEX010 is currently supplied to over 70 clinical research sites globally and is being studied for various mental health conditions, including alcohol use disorder and treatment-resistant depression [4][8]. - The drug candidate has received authorization for clinical trials from both Health Canada and the U.S. Food and Drug Administration, demonstrating positive Phase 2 clinical data in alcohol use disorder [5]. Group 2: Strategic Rationale - The integration of the Researgency.ai platform is a strategic move for Red Light to enhance its psychedelic drug development capabilities, focusing on research planning, scenario simulation, and protocol optimization [3][6]. - The Researgency.ai platform is designed to create autonomous research loops that can generate and optimize study scenarios, compressing timelines and expanding viable options for clinical trials [6][11]. Group 3: Management Commentary - Management emphasizes that utilizing Kala Bio's AI platform is a natural progression in building a leading psychedelic drug development operation, aiming to strengthen study designs and accelerate decision-making processes [7]. - The CEO of Filament Health highlights the importance of advanced analytical tools in evaluating clinical development strategies as the program evolves [7]. - Kala Bio's CEO notes that the deployment of Researgency.ai addresses high-value, data-intensive challenges in psychedelic drug development, which can significantly impact clinical scenario evaluations [7].